Table 5.
Anti-VEGF injections given in study eye
| Cohort | Patient ID | Time since enrollment (weeks) | Preferred anti-VEGF therapy | Indication |
|---|---|---|---|---|
| 1 | 1A | 24 | Ranibizumab | Intraretinal or subretinal fluid |
| 4 | 4E | 24 | Aflibercept | Intraretinal or subretinal fluid |
| 31 | Aflibercept | Intraretinal or subretinal fluid | ||
| 38 | Aflibercept | Intraretinal or subretinal fluid | ||
| 42 | Aflibercept | Intraretinal or subretinal fluid | ||
| 48 | Aflibercept | Intraretinal or subretinal fluid | ||
| 4G | 12 | Aflibercept | Intraretinal or subretinal fluid | |
| 20 | Aflibercept | Intraretinal or subretinal fluid | ||
| 24 | Aflibercept | Intraretinal or subretinal fluid | ||
| 32 | Aflibercept | Intraretinal or subretinal fluid | ||
| 4H | 8 | Aflibercept | Intraretinal or subretinal fluid | |
| 12 | Aflibercept | Intraretinal or subretinal fluid | ||
| 20 | Aflibercept | Intraretinal or subretinal fluid | ||
| 4I | 48 | Aflibercept | Subretinal hemorrhage | |
| 4J | 10 | Bevacizumab | Subretinal hemorrhage | |
| 12 | Bevacizumab | Subretinal hemorrhage | ||
| 16 | Bevacizumab | Subretinal hemorrhage | ||
| 24 | Bevacizumab | Subretinal hemorrhage | ||
| 30 | Bevacizumab | Subretinal hemorrhage | ||
| 4K | 8 | Bevacizumab | Intraretinal or subretinal fluid | |
| 16 | Bevacizumab | Intraretinal or subretinal fluid | ||
| 20 | Aflibercept | Intraretinal or subretinal fluid | ||
| 42 | Aflibercept | Subretinal hemorrhage | ||
| 4L | 6 | Aflibercept | Intraretinal or subretinal fluid | |
| 20 | Aflibercept | Intraretinal or subretinal fluid | ||
| 26 | Aflibercept | Intraretinal or subretinal fluid | ||
| 39 | Aflibercept | Intraretinal or subretinal fluid |